JuneBrain

JuneBrain operates at the intersection of medical devices, health diagnostics, neurotechnology, and digital health. Its stated approach uses retinal imaging as a way to support remote, quantitative monitoring of neurological conditions, including multiple sclerosis. The product lineup combines Neuro-i SS-OCT, a portable point-of-care optical coherence tomography device, with JuneBrain Reading Center, an AI-supported service for quantitative OCT analysis with clinician quality control. This pairing distinguishes its offering within the profile: it combines imaging hardware and interpretation services rather than describing software-only monitoring. The company’s longer-term ambition is to extend monitoring beyond MS to a broader neurodegenerative disease population, while its stated access goal includes underserved communities. Its positioning should therefore be assessed against the broader medical imaging and remote diagnostics landscape, with differentiation centered on retinal data, portable OCT, and quantitative analysis. Clinical validation, regulatory status, deployment scale, and commercial adoption are not established by the available company information, limiting conclusions about its current market share or relative performance.

JuneBrain was founded in 2017 and remains a small organization, with its employee range listed as 1–10. Its financing history combines grants, early-stage equity, non-equity assistance, and venture investment. The earliest listed amount is a $1 million National Science Foundation grant on June 10, 2021, followed by a $235,000 pre-seed round in June 2022 and $77,980 in equity crowdfunding in March 2023. In September 2024, the company received a $300,000 Medical Device Innovation Consortium award and a separate $200,000 TEDCO grant. The $450,000 venture round dated October 8, 2025 marks a later disclosed equity financing milestone. Recognition at the 2025 BioChallenge and additional non-equity assistance in January 2026 add evidence of continued external support. The April 3, 2026 venture round lists Gulf South Angels and New Orleans BioFund, but its amount is undisclosed. The stated total funding is $2,537,980, while the individually quantified rounds in the available list do not account for that full total.